Roidipedia — compound reference & reporting

Latest

1 Mar

Imaging study links long-term anabolic-steroid use to reduced heart function that persists after stopping

An echocardiographic study of weightlifters found lower ejection fraction and enlarged hearts in anabolic-androgenic steroid users, with abnormalities still present years after discontinuation.

enwy0 comments

11 Nov

Trial data

SELECT trial: semaglutide 2.4 mg cuts major cardiovascular events 20% in obesity without diabetes

The first cardiovascular outcomes trial of a weight-loss drug found a 20% relative reduction in MACE among people with established heart disease.

enwy0 comments

29 Sept

Regulation

FDA places BPC-157 in Category 2 of the 503A bulk-substances list, citing safety data gaps

The agency assigned the research peptide to a category that effectively bars its use in pharmacy compounding, alongside more than a dozen other peptides.

enwy0 comments

16 Jul

Trial data

TRAVERSE trial finds testosterone therapy noninferior to placebo for major cardiac events

The largest randomised cardiovascular-safety trial of testosterone-replacement therapy reported no increase in major adverse cardiac events, but flagged higher rates of atrial fibrillation, pulmonary embolism and acute kidney injury.

enwy0 comments

26 Jun

Trial data

Retatrutide phase 2 trial reports up to 24.2% mean weight loss at 48 weeks

Lilly's triple GLP-1/GIP/glucagon agonist showed dose-dependent weight reduction in a phase 2 obesity trial published in NEJM.

enwy0 comments

WADA's 2026 Prohibited List clarifies that esters of anabolic agents are banned

FDA removes cardiovascular boxed warning from testosterone products, adds blood-pressure warning

FDA winds down enforcement discretion for compounded tirzepatide and semaglutide after shortages resolve

Latest

Imaging study links long-term anabolic-steroid use to reduced heart function that persists after stopping

SELECT trial: semaglutide 2.4 mg cuts major cardiovascular events 20% in obesity without diabetes

FDA places BPC-157 in Category 2 of the 503A bulk-substances list, citing safety data gaps

TRAVERSE trial finds testosterone therapy noninferior to placebo for major cardiac events

Retatrutide phase 2 trial reports up to 24.2% mean weight loss at 48 weeks

From the reference

Compound index